Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,839 USD | +3,58% | +14,12% | +64,51% |
06/05 | CHEMOMAB THERAPEUTICS LTD. : Oppenheimer past advies aan | ZM |
10/04 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 11,51 mln. 10,68 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -15 mln. -13,93 mln. | Nettowinst (verlies) 2025 * | -22 mln. -20,43 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-14
x | K/w-verhouding 2025 * |
-18,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 4,97% |
Recentste transcriptie over Chemomab Therapeutics Ltd.
1 dag | +3,58% | ||
1 week | +14,12% | ||
Lopende maand | +19,86% | ||
1 maand | +6,20% | ||
3 maanden | +39,83% | ||
6 maanden | +39,83% | ||
Lopend jaar | +64,51% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 22-09-11 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 01-01-20 |
Chief Tech/Sci/R&D Officer | 56 | 14-11-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 01-04-20 |
Nissim Darvish
CHM | Chairman | 59 | 16-03-21 |
Claude Nicaise
BRD | Director/Board Member | 71 | 16-03-21 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
10-05-24 | 0,839 | +3,58% | 66 540 |
09-05-24 | 0,81 | +11,72% | 124 859 |
08-05-24 | 0,725 | -18,42% | 426 854 |
07-05-24 | 0,8887 | +4,21% | 404 239 |
06-05-24 | 0,8528 | +15,24% | 1 262 762 |
uitgestelde koers Nasdaq, 10 mei 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+64,51% | 11,51 mln. | |
+3,91% | 108 mld. | |
+10,87% | 104 mld. | |
+1,28% | 22,33 mld. | |
-13,14% | 22,19 mld. | |
-7,05% | 18,69 mld. | |
-38,36% | 17,74 mld. | |
-10,66% | 17,64 mld. | |
+3,75% | 14,05 mld. | |
+36,70% | 12,51 mld. |